Imunon (IMNN)

• Market cap: $12.2M
• 1 day: -4.34%
• 5 days: 2.58%
• 1 month: -0.5%
• 3 months: -28.85%
• 6 months: -73.3%
• Year to date: -71.02%
• 1 year: -63.78%
• 5 years: -97.14%
• 10 years: -99.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Employees: 25